IDEXX Laboratories (NASDAQ:IDXX) Releases FY 2026 Earnings Guidance

IDEXX Laboratories (NASDAQ:IDXX) updated its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 14.960-15.160 for the period, compared to the consensus EPS estimate of 14.860. The company issued revenue guidance of $4.7 billion-$4.8 billion, compared to the consensus revenue estimate of $4.7 billion.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX opened at $671.64 on Tuesday. The stock has a market cap of $52.91 billion, a PE ratio of 47.23 and a beta of 1.55. IDEXX Laboratories has a 1 year low of $500.61 and a 1 year high of $769.98. The firm has a fifty day moving average price of $536.56 and a 200-day moving average price of $573.88. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Monday, November 2nd. The company reported $3.96 earnings per share for the quarter, beating analysts’ consensus estimates of $3.71 by $0.25. The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.19 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. IDEXX Laboratories’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.22 EPS. Equities analysts anticipate that IDEXX Laboratories will post 14.81 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IDXX has been the topic of a number of recent analyst reports. Jefferies Financial Group decreased their price target on IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating on the stock in a report on Tuesday, October 20th. The Goldman Sachs Group began coverage on IDEXX Laboratories in a research report on Friday, October 16th. They issued a “buy” rating and a $740.00 price objective on the stock. KeyCorp initiated coverage on IDEXX Laboratories in a research note on Monday, October 12th. They issued a “sector weight” rating for the company. Citigroup increased their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Finally, Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Eight research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $727.75.

Insider Activity at IDEXX Laboratories

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the business’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the transaction, the director owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. The trade was a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.79% of the company’s stock.

IDEXX Laboratories News Summary

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Q3 beat estimates: IDEXX reported adjusted EPS of approximately $3.96–$3.98, above the $3.71 consensus estimate, while revenue rose 9.9% year over year to about $1.21 billion, exceeding expectations of $1.19 billion. IDEXX Laboratories earnings report
• Positive Sentiment: Raised 2026 guidance: The company now expects full-year EPS of $14.96–$15.16, above the $14.86 analyst consensus, and revenue of $4.7–$4.8 billion, with the top end exceeding expectations. IDEXX raises forecast
• Positive Sentiment: Recurring diagnostics remained the growth engine: Diagnostics sales to veterinarians increased about 11%, supporting stronger revenue, earnings and investor expectations for continued execution. Morgan Stanley reiterated its Buy rating and maintained an $805 price target. Morgan Stanley reiterates Buy rating
• Neutral Sentiment: The earnings-driven rally was substantial, leaving IDXX near the upper portion of its recent trading range and potentially increasing the risk of profit-taking despite the improved fundamentals. IDEXX surges on Q3 beat
• Negative Sentiment: Margin and demand caveat: Reports indicated that the higher profit outlook was not primarily driven by stronger testing demand, while the margin outlook softened and veterinary visits remained weak. These factors could limit the durability of the rally. IDEXX sales rise as margin outlook slips

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.